alternate pov, page-7

Writer 7/9/11 post attendance @ Sydney briefing :

"Lsst but not least, was the question of capital requirements going forward. Alan stated they have enough money through to end of 2012 when production will really start to ramp up. In the face of some fairly robust questioning, he discussed the possibility of up-front license fees for the various products in various Therapeutic Drug Classes, as well as the likelihood of several of these products being funded through to production in the same way Sanofi funded the Unifill.

Due to aforementioned stringent SEC requirenments, he could not, and cannot, say with any certainty when these may be delivered. But he repeated several times that over the next 3-12 months they expected various announcements about these developments to be forthcoming.

Both he and Ramin also talked about the growth of US funds on the UNIS register. By way of example, Alan talked about Fidelity, the largest fund manager in the world, with the pre-emminent Medical Device Fund. After visiting Unilife and conducting extensive due diligence on Unilife, Fidelity began buying on-market in March. Alan stated that they have several major funds including Fidelity who are pressing Unilife "to take their money" or words to that effect.

So there are multiple options. I personally would be surprised if we see another SPP. US-based insto placements yes, but SPP? Alan also stated that, not only as the largest shareholder, but for all shareholders, he was very mindful of further dilution and wouild take whatever was in the best interests of all shareholders to minimise this.

One last thing. Ramin spoke at length about his first task when he joined, which was to write a business plan. He explained what went into it - his many years of industry knowledge and expertise, his personal relationships with senior executives the world over, and how he brings these relationships with him to Unilife, his knowledge of pharma companies, how they work, their drug pipelines, the device industry generally, where it is now, where it's going, and as a PHD in the field, his extensive knowledge of molucular drugs etc. etc., and how he triangulated all that into the business plan.

He ended by saying that, in his opinion, Unilife was going to be "Colossal."

On that note, sorry it's taken so long, but IMO it was a compelling presentation. Much more in there, and will get to the rest of it later. Particularly about the ramp up to full production which will being in earnest in the next six months.....

....also about how our products extend patent life. How, once approved, a drug generally has ?nly about 12 years patent life left. But that Unilife's IP can extend that by a further 8 years to 20 years. Take a $250 million a year drug, conservative for many of these drugs, Alan's words, not mind, extendthat by another 8 years and youve handed the pharma an additional US$2 billion in revenue. How much are they going to pay up-front to secure that right?'....

The end....or is it just the beginning!

BTW, Sorry to miss you CREDIT. Had second thoughts about the AB jersey, but was in a black tee, and kinda hoped the red Duty Free bag might give it away.

Redpill, if you were within earshot of me telling who I did about the black tee I was wearing, why didn't you introduce yourself? Maybe next time. :)

Good luck everyone. We ain't going to need it. IMO."

Writer , ...enjoy your inputs , but even Dino is recognising reality now !! Well done Dino.TA from me .
Writer , perhaps you would like to provide us with a self critique of your 7/9/11 post , in the context of today's announcement ..nothing personal mate ....but surely you earlier post today was a fairy story !!.
Q